Janice K Ryu, M.D.
Investigator
Dr. Janice Ryu is a board-certified radiation oncologist with extensive expertise in the treatment of cancer using advanced radiation therapies. She earned her B.A. in Biochemistry from Harvard University and her M.D. from the University of California, San Francisco, followed by residency and chief residency training at Memorial Sloan-Kettering Cancer Center.
Dr. Ryu has held numerous academic and leadership roles at the University of California, Davis, including Interim Chair, Clinical Director, and Residency Director in the Department of Radiation Oncology. She later served as an attending radiation oncologist at Radiological Associates of Sacramento and currently practices with Sutter Medical Group.
A Fellow of the American College of Radiology, Dr. Ryu has received multiple honors for teaching and clinical excellence. She is an active contributor to oncology research, with numerous peer-reviewed publications and involvement in national cooperative groups advancing cancer treatment.
Clinical trials
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Neuroblastoma ANBL2131
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Pediatric Leukemia AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse.
Status: Open to Enrollment
- Clinical trial
Pediatric B-Lymphoblastic Leukemia COG AALL1732
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyLy
Status: Open to Enrollment
- Clinical trial
Pediatric Long Term Follow Up ALTE05N1
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Status: Open to Enrollment